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Abstract 
Objectives: The study sought to assess the prognostic impact of type 2 diabetes in patients presenting with ven‑
tricular tachyarrhythmias on admission.
Background: Data regarding the prognostic outcome of diabetics presenting with ventricular tachyarrhythmias is 
limited.
Methods: A large retrospective registry was used including all consecutive patients presenting with ventricular 
tachycardia (VT) and fibrillation (VF) on admission from 2002 to 2016. Patients with type 2 diabetes (diabetics) were 
compared to non‑diabetics applying multivariable Cox regression models and propensity‑score matching for evalua‑
tion of the primary prognostic endpoint of long‑term all‑cause mortality at 2 years. Secondary prognostic endpoints 
were cardiac death at 24 h, in‑hospital death at index, all‑cause mortality at 30 days, all‑cause mortality in patients 
surviving index hospitalization at 2 years (i.e. “after discharge”) and rehospitalization due to recurrent ventricular tach‑
yarrhythmias at 2 years.
Results: In 2411 unmatched high‑risk patients with ventricular tachyarrhythmias, diabetes was present in 25% 
compared to non‑diabetics (75%). Rates of VT (57% vs. 56%) and VF (43% vs. 44%) were comparable in both groups. 
Multivariable Cox regression models revealed diabetics associated with the primary endpoint of long‑term all‑cause 
mortality at 2 years (HR = 1.513; p = 0.001), which was still proven after propensity score matching (46% vs. 33%, log 
rank p = 0.001; HR = 1.525; p = 0.001). The rates of secondary endpoints were higher for in‑hospital death at index, 
all‑cause mortality at 30 days, as well as after discharge, but not for cardiac death at 24 h or rehospitalization due to 
recurrent ventricular tachyarrhythmias.
Conclusion: Presence of type 2 diabetes is independently associated with an increase of all‑cause mortality in 
patients presenting with ventricular tachyarrhythmias on admission.
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Introduction
According to estimates by the international diabetes 
federation (IDF) 642 million people worldwide will suf-
fer from diabetes mellitus type 2 in 2040. Therefore, dia-
betes represents a major burden to healthcare systems 
across the world [1, 2]. One of the most common causes 
of death in diabetics is sudden cardiac death (SCD) [3]. 
SCD accounts for 15–20% of all deaths in the Western 
world [4]. Furthermore, patients suffering from ven-
tricular tachyarrhythmias and SCD are associated with 
poor outcome [5]. The identification of potential risk fac-
tors associated with increasing overall and cardiovascular 
mortality or SCD is of great medical interest.
The presence of type 2 diabetes constitutes a well-
established cardiovascular risk factor. 70% of all hospi-
talizations in diabetics  are due to vascular diseases and 
demand multidisciplinary therapies [6]. Type 2 diabetes 
affects all types of vessels regardless of vessel-size [7]. It 
induces microangiopathies such as diabetic retinopa-
thy, nephropathy and neuropathy and  macro-angiopa-
thies including peripheral and coronary artery disease 
(CAD) [6]. In addition, prediabetes and type 2 diabe-
tes  are independently associated with the development 
of sub-clinical myocardial injury [8]. In turn, CAD and 
acute myocardial infarction (AMI) are the most com-
mon causes for the development of ventricular tachyar-
rhythmias and SCD [9, 10]. Over the last decades, type 
2 diabetes has been evaluated as an independent risk 
factor for ventricular tachyarrhythmias and SCD [5, 11, 
12]. However, it is still unclear whether type 2 diabetes 
may influence long-term prognosis of patients present-
ing with life-threatening ventricular tachyarrhythmias on 
admission.
Therefore, this study evaluates the secondary prognos-
tic impact of type 2 diabetes in patients presenting with 
ventricular tachyarrhythmias on admission.
Methods
Study patients, design and data collection
The present study included retrospectively  all patients 
presenting with ventricular tachyarrhythmias from 
2002 until 2016 at one institution. All relevant clinical 
data related to the index event was documented using 
patients’ files, daily records, documentation from diag-
nostic examinations and laboratory values, electro-
cardiograms (ECG), device recordings, and all further 
information derived from the electronic hospital infor-
mation system.
Ventricular tachyarrhythmias comprised ventricu-
lar tachycardia (VT) and fibrillation (VF), as defined by 
current international guidelines [5]. Sustained VT was 
defined by VT with a duration of more than 30 s or addi-
tional hemodynamic collapse within 30 s. Non-sustained 
VT are defined by less than 30  s. VT comprised wide 
QRS complexes (≥ 120  ms) at a rate greater than 100 
beats/min [5]. Ventricular tachyarrhythmias were doc-
umented by 12-lead ECG, ECG tele-monitoring and 
implantable cardioverter defibrillators (ICD). In case of 
unstable course or during cardiopulmonary  resuscita-
tion (CPR) documentation was performed  by external 
defibrillator monitoring. Documented VF was treated by 
external defibrillation and in case of prolonged instability 
with additional intravenous anti-arrhythmic drugs during 
CPR [5].
Further documented data contained baseline charac-
teristics, prior medical history, prior medical treatment, 
length of index stay, detailed findings of laboratory val-
ues at baseline, data derived from all non-invasive or 
invasive cardiac diagnostics and device therapies. These 
included  coronary angiography, electrophysiological 
examination, prior or newly implanted ICDs, pacemak-
ers or cardiac contractility modulators (CCM), which 
were already implanted at index or at follow-up. Imaging 
modalities comprised echocardiography or cardiac mag-
netic resonance imaging (cMRI). The overall presence of 
an activated ICD summarizes the total sum of all patients 
with either a prior implanted ICD before admission, 
those undergoing new ICD implantation at index stay, 
as well as those with ICD implantation at the complete 
follow-up period after index hospitalization, referring to 
sole ICD, subcutaneous-ICD (s-ICD) and cardiac resyn-
chronization therapy with defibrillator function (CRT-D). 
Pharmacological treatment was documented according 
to the discharge medication of patients surviving index 
hospitalization. Rates of overall ICDs and of pharmaco-
logical therapies are referred to the number of surviving 
patients being discharged from index hospitalization.
Documentation period lasted from index event until 
2016. Documentation of all medical data was performed 
by independent cardiologists at the patients´ individual 
period of hospitalization blinded to final data analyses.
The present study is derived from an analysis of the 
“Registry of Malignant Arrhythmias and Sudden Car-
diac Death-Influence of Diagnostics and Interventions 
(RACE-IT)” and represents a single-center registry 
including retrospectively  consecutive patients present-
ing with ventricular tachyarrhythmias and SCD being 
acutely admitted to the University Medical Center Man-
nheim (UMM), Germany (clinicaltrials.gov identifier: 
NCT02982473) from 2002 until 2016. The registry was 
carried out according to the principles of the declaration 
of Helsinki and was approved by the medical ethics com-
mittee II of the Faculty of Medicine Mannheim, Univer-
sity of Heidelberg, Germany.
The medical center covers a general emergency depart-
ment (ED) for emergency admission of traumatic, 
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surgical, neurological and cardiovascular conditions. 
Interdisciplinary consultation is an inbuilt feature of 
this 24/7 service, and is connected to a stroke unit, four 
intensive care units (ICU) with extracorporeal life sup-
port and a chest pain unit (CPU) to alleviate rapid triage 
of patients. The cardiologic department itself includes 
24 h catheterization and electrophysiologic laboratories, 
a hybrid operating room and telemetry units.
Definition of study groups, inclusion and exclusion criteria
For the present analysis risk stratification was performed 
according to the presence of type 2 diabetes (diabetics) 
compared to non-diabetics following the guidelines of the 
international diabetes federation [13]. Diabetes mellitus 
was defined as HbA1c ≥ 6.5% (48  mmol/mol) or fasting 
plasma glucose level ≥ 7.0  mmol/L (≥126  mg/dl) or 2-h 
post-load plasma glucose level ≥ 11.1 mmol/L (≥200 mg/
dL) [13, 14]. Patients with previously diagnosed and cur-
rently treated type 2 diabetes were included.
Overall exclusion criteria comprised patients with 
type 1 diabetes, patients with SCD without documenta-
tion of index ventricular tachyarrhythmias (VT or VF), 
and patients without complete follow-up data regarding 
mortality. Each patient was counted only once for inclu-
sion when presenting with the first episode of ventricular 
tachyarrhythmias.
Study endpoints
The primary prognostic endpoint was all-cause mortality 
at long-term follow-up. Secondary prognostic endpoints 
were early  cardiac death at 24 h, in-hospital death at 
index, all-cause mortality at 30 days, all-cause mortality 
in patients surviving index hospitalization at 2 years (i.e. 
“after discharge”) and re-hospitalization due to recurrent 
ventricular tachyarrhythmias at 2 years. Early cardiac 
death was defined as occurring < 24 h after onset of ven-
tricular tachyarrhythmias or an assumed unstable cardiac 
condition on index admission [5].
Overall follow-up lasted until 2016. All-cause mortal-
ity was documented using our electronic hospital infor-
mation system and by directly contacting state resident 
registration offices (“bureau of mortality statistics”) 
across Germany. Identification of patients was verified by 
place of name, surname, day of birth and registered living 
address. Lost to follow-up rate was 1.7% (n = 48) regard-
ing survival until the end of the follow-up period.
Statistical methods
Quantitative data are presented as mean ± standard 
error of mean (SEM), median and interquartile range 
(IQR), and ranges depending on the distribution of the 
data and were compared using the Student’s t test for 
normally distributed data or the Mann–Whitney U test 
for nonparametric data. Deviations from a Gaussian dis-
tribution were tested by the Kolmogorov–Smirnov test. 
Spearman’s rank correlation for nonparametric data was 
used to test univariate correlations. Qualitative data are 
presented as absolute and relative frequencies and com-
pared using the  Chi2 test or the Fisher’s exact test, as 
appropriate.
Firstly, overall data of consecutive patients on admis-
sion are given for the entire unmatched cohort in order 
to present the real-life character of health-care supply 
at our institution in between 2002 and 2016. Here, mul-
tivariable Cox regression models were applied for the 
evaluation of the primary prognostic endpoint within the 
total study cohort for diabetics compared to non-diabet-
ics. Then uni- and multivariable Cox regression models 
were applied for the primary prognostic endpoint for 
diabetes in the sub-groups of males, females, age above 
or below 70 years, VT, VF, chronic kidney disease, acute 
myocardial infarction (AMI), (non-)ST segment eleva-
tion myocardial infarction (NSTEMI and STEMI), CAD, 
non-CAD, left ventricular ejection fraction (LVEF) above 
or below 55%, overall ICD, primary and secondary pre-
ventive ICD, non-ICD patients. Multivariable Cox regres-
sion models were adjusted for the following covariables: 
age, gender, chronic kidney disease, CAD, CPR, AMI, 
LVEF < 55%, index ventricular tachyarrhythmia (i.e., VT/
VF) and overall ICD.
Secondly, propensity score matching was applied. 
There is a relevant and increasing demand from patients, 
clinicians and within the health care system in gen-
eral for growing evidence from non-randomized stud-
ies. There are simply too many medically relevant 
questions  and  hypotheses, which will never be investi-
gated within randomized controlled trials due to sev-
eral reasons (i.e. funding, recruitment, difficult study 
settings, high-risk patients, etc.). Therefore, we felt that 
the method of propensity score matching would be a 
reasonable additional statistical method beside multi-
variable Cox regression models for the purpose of the 
present study evaluating the prognostic impact of dia-
betes in high-risk patients presenting with ventricular 
tachyarrhythmias on admission. These high-risk patients 
are usually excluded from randomized controlled tri-
als (RCT). In a RCT patients with or without a specific 
treatment would have a 50% chance to be treated and 
balanced measured and unmeasured baseline character-
istics would be expected. However, patients with differ-
ent disease entities may not be randomized in real-life 
(such as diabetics vs. non-diabetics) due to different 
pathophysiologies and treatment recommendations. An 
observational study usually recruits consecutive real-
life patients without randomization resulting in varying 
chances between 0% and 100% to receive imbalances in 
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baseline characteristics and treatments. Therefore, dif-
ferences of outcomes in specific disease groups might be 
explained by heterogeneous distribution of baseline char-
acteristics and applied therapies. To further reduce this 
selection bias, we used 1:1 propensity-scores for diabetics 
vs. non-diabetics to assemble matched cohorts, in which 
patients would be well-balanced regarding all measured 
baseline characteristics. 1:1 propensity score matching 
was performed including the entire study cohort, apply-
ing a non-parsimonious multivariable logistic regression 
model using diabetics as the dependent variables [15, 16].
Propensity scores were created according to the pres-
ence of the following independent variables: age, gender, 
chronic kidney disease, CAD, acute myocardial infarc-
tion, LVEF, CPR, index ventricular tachyarrhythmia (i.e., 
VT/VF) and overall ICD. Based on the propensity score 
values counted by logistic regression, for each diabetic 
one non-diabetic in the control group with a similar pro-
pensity score value was found (accepted difference of 
propensity score values < 5%). Uni-variable stratification 
was performed using the Kaplan–Meier method with 
comparisons between groups using uni-variable hazard 
ratios (HR) given together with 95% confidence intervals, 
according to the presence of diabetics and non-diabetics 
within the propensity-matched cohorts.
Follow-up periods for evaluation of long-term all-cause 
mortality were set at 2  years according to the median 
survival time of diabetic patients to guarantee complete 
follow-up of at least 50% of patients. Patients not meeting 
long-term follow-up were censored.
The result of a statistical test was considered signifi-
cant for p < 0.05, p values ≤ 0.1 were defined as a statisti-
cal trend. SAS, release 9.4 (SAS Institute Inc., Cary, NC, 
USA) and SPSS (Version 25, IBM Armonk, New York, 
USA) were used for statistics.
Results
Entire, unmatched real‑life cohort
In the entire unmatched real-life cohort of 2411 consecu-
tive patients presenting with ventricular tachyarrhyth-
mias on admission the prevalence of type 2 diabetes was 
25%. As shown in Table 1 (left columns) rates of VT and 
VF were comparable between diabetics and non-diabet-
ics (57% vs. 43%) and most patients were males (72%). 
Diabetics were older (median 71 vs. 67  years) and had 
higher rates of arterial hypertension, hyperlipidaemia, 
prior heart failure, prior AMI, prior CAD, atrial fibril-
lation, chronic kidney disease, stroke and CPR, whereas 
rates of AMI at index were similar. Furthermore, dia-
betics had higher rates of coronary 3 vessel disease with 
chronic total occlusions and higher rates of LVEF < 35%.
Rates of electrophysiological examination were higher 
in non-diabetics compared to diabetics (27% vs. 18%). 
Morphologies of induced VT were similar in both 
groups. Non-diabetics underwent ablation therapy for 
VT more often (7% vs. 2%) with a median LVEF 42% (IQR 
22–57%) in these patients (Table 1, left columns). Overall 
rates of ICDs were similar in diabetics and non-diabetics 
(50% vs. 54%), respectively for CRT-D recipients without 
further differences in bipolar and multipolar electrodes. 
ICD implantation was indicated more often for second-
ary prevention in non-diabetics and for primary preven-
tion in diabetics (Table 1, left columns).
Diabetics were more often treated with beta blockers, 
angiotensin converting enzyme inhibitors (ACEi), angio-
tensin receptor blockers (ARB), statins, digitalis and ami-
odarone and vitamin K antagonists. In contrast, rates 
of sotalol, novel oral anticoagulants (NOAC) and low-
molecular heparin were similar (Table  1, left columns). 
Regarding antidiabetic medication (Table  2), most dia-
betics were treated with insulins, followed by metformin 
and sulfonylurea. Glitazone, dipeptidyl peptidase-4 
(DPP-4) inhibitors and sodium/glucose cotransporter (2) 
(SGLT(2)) -inhibitors were administered rarely (less than 
4%).
Figure 1 (left panel) illustrates significantly higher rates 
of the primary endpoint of all-cause mortality at 2 years 
after presenting with ventricular tachyarrhythmias on 
hospital admission (51% vs. 36%, log rank p = 0.001; 
HR = 1.513, 95% CI 1.322–1.731; p = 0.001). Further-
more, diabetics were associated with higher rates of sec-
ondary endpoints, including in-hospital death, all-cause 
mortality at 30 days and after discharge, whereas cardiac 
death at 24 hours and rehospitalization due to recurrent 
ventricular tachyarrhythmias were similar in both groups 
(Table 6, right columns).
Multivariable Cox regression analyses within the 
entire unmatched “real-life” cohort revealed diabetics 
being significantly associated with the primary prognos-
tic endpoint of long-term all-cause mortality at 2  years 
(HR = 1.209; 95% CI 1.010–1.447; p = 0.039) (Table  3). 
Diabetics sustained significant impact on long-term all-
cause mortality in the sub-groups of males, age > 70 years, 
VT, AMI, NSTEMI, overall CAD, multi-vessel CAD and 
ICD-recipients, respectively with indication for primary 
prevention (Table 4). Notably, insulin dependent diabet-
ics were associated with increased long-term all-cause 
mortality, whereas treatment with metformin and other 
oral antidiabetic drugs in diabetics revealed prognostic 
benefit (unadjusted hazard ratios, Table  5). In CRT-D 
patients no differences were seen in between patients 
with multipolar compared to bipolar ICD electrodes 
(non-diabetics: 18% vs. 14% p = 0.836; diabetics: 26% vs. 
17% p = 0.417; data not shown).  
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Table 1 Study population
Characteristic Before matching (n = 2411) After matching (n = 894)
Non‑diabetics 
(n = 1798; 75%)
Diabetics 
(n = 613; 25%)
p value Non‑diabetics 
(n = 447; 50%)
Diabetics 
(n = 447; 50%)
p value
Ventricular tachyarrhythmias, n (%)
 Ventricular tachycardia 1006 (56) 350 (57) 0.622 275 (62) 272 (61) 0.837
  Monomorphic 973 (97) 339 (97) 0.901 267 (97) 262 (96) 0.615
  Polymorphic 33 (3) 11 (3) 8 (3) 10 (4)
 Ventricular fibrillation 792 (44) 263 (43) 0.622 172 (39) 175 (39) 0.837
Age, median (range) 67 (14–97) 71 (33–95) 0.001 70 (21–94) 71 (33–91) 0.040
Male gender, n (%) 1288 (72) 440 (72) 0.946 348 (78) 331 (74) 0.183
Cardiovascular risk factors, n (%)
 Arterial hypertension 891 (50) 464 (76) 0.001 287 (64) 351 (79) 0.001
 Hyperlipidemia 448 (25) 210 (34) 0.001 152 (34) 164 (37) 0.401
 Smoking 478 (27) 161 (26) 0.876 133 (30) 128 (29) 0.713
 Cardiac family history 188 (11) 34 (6) 0.001 53 (12) 26 (6) 0.001
Comorbidities, n (%)
 Prior heart failure 355 (20) 196 (32) 0.001 143 (32) 172 (39) 0.042
 Prior coronary artery disease 608 (34) 336 (55) 0.001 248 (56) 270 (60) 0.136
 Prior myocardial infarction 363 (20) 180 (29) 0.001 147 (33) 150 (34) 0.831
 Valvular heart disease 138 (8) 74 (12) 0.001 46 (10) 61 (14) 0.122
 Acute myocardial infarction 507 (28) 180 (29) 0.581 123 (28) 128 (29) 0.710
  STEMI 184 (10) 52 (9) 0.208 29 (7) 38 (9) 0.253
  NSTEMI 323 (18) 128 (21) 0.110 94 (21) 90 (20) 0.741
 Non‑ischemic cardiomyopathy 96 (5) 27 (4) 0.364 32 (7) 27 (6) 0.501
 Atrial fibrillation 492 (27) 223 (36) 0.001 155 (35) 170 (38) 0.297
 Stroke (ischemic or hemorrhage) 42 (2) 30 (5) 0.001 12 (3) 20 (5) 0.150
 Chronic kidney disease 801 (46) 387 (64) 0.001 25 (56) 27 (62) 0.048
 Cardiopulmonary resuscitation 831 (52) 425 (57) 0.001 175 (39) 198 (44) 0.119
  In hospital 310 (17) 169 (28) 0.001 77 (17) 109 (24) 0.008
  Out of hospital 521 (29) 139 (23) 0.001 98 (22) 89 (20) 0.459
Coronary angiography, overall, n (%) 1055 (59) 362 (59) 0.870 291 (65) 295 (66) 0.778
 Coronary artery disease 742 (41) 305 (50) 0.001 233 (52) 249 (56) 0.155
  None 313 (30) 57 (16) 0.001 58 (20) 46 (16) 0.169
  1‑vessel 244 (23) 82 (23) 0.853 74 (25) 66 (22) 0.386
  2‑vessel 249 (24) 86 (24) 0.952 73 (25) 73 (25) 0.924
  3‑vessel 249 (24) 137 (38) 0.001 86 (30) 110 (37) 0.047
  Chronic total occlusion 190 (18) 100 (28) 0.001 70 (24) 82 (28) 0.301
  Presence of CABG 110 (10) 73 (20) 0.001 49 (17) 66 (22) 0.092
 Percutaneous coronary intervention 479 (45) 163 (45) 0.902 113 (39) 123 (42) 0.480
Left ventricular ejection function, n (%)
 LVEF ≥ 55% 431 (24) 101 (16) 0.001 102 (23) 100 (22) 0.873
 LVEF 54–35% 449 (25) 160 (26) 0.579 156 (35) 139 (31) 0.227
 LVEF < 35% 427 (24) 211 (34) 0.001 189 (42) 208 (47) 0.201
 Not documented 491 (27) 141 (23) – – – –
Electrophysiological examination, n (%) 481 (27) 111 (18) 0.001 128 (30) 88 (20) 0.001
 Induced ventricular tachycardia
  Inferior 11 (2) 2 (2) 0.753 3 (2) 2 (2) 0.973
  Apical 152 (32) 40 (36) 0.368 42 (33) 35 (40) 0.294
  Septal 18 (4) 1 (0.9) 0.126 6 (5) 0 (0) 0.083
  Lateral 5 (1) 4 (4) 0.069 0 (0) 3 (3) 0.066
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Propensity matched cohort
After applying propensity score matching for the com-
parison of diabetics vs. non-diabetics (447 matched pairs) 
comparable rates were achieved for ventricular tachyar-
rhythmias at index, gender, AMI, atrial fibrillation, CPR, 
overall CAD, LVEF, overall ICD and medication at dis-
charge. There were only slight differences left for age (71 
vs. 70 years), stroke (62% vs. 56%), 3-vessel CAD (37% vs. 
30%) and chronic kidney disease (62% vs. 56%) between 
diabetics and non-diabetics (Table 1, right columns).
Figure  1 (right panel) illustrates significantly higher 
rates of the primary endpoint of all-cause mortality at 
2 years even after propensity score matching in patients 
presenting with ventricular tachyarrhythmias on hospital 
admission (46% vs. 33%, log rank p = 0.001; HR = 1.525, 
95% CI 1.234–1.885; p = 0.001). Furthermore, diabet-
ics were associated with higher rates of secondary end-
points, including in-hospital death, all-cause mortality at 
30 days and after discharge, whereas cardiac death at 24 
hours and rehospitalization due to recurrent ventricular 
tachyarrhythmias were similar in both groups, even after 
propensity score matching (Table 6, right columns).
Table 1 (continued)
Characteristic Before matching (n = 2411) After matching (n = 894)
Non‑diabetics 
(n = 1798; 75%)
Diabetics 
(n = 613; 25%)
p value Non‑diabetics 
(n = 447; 50%)
Diabetics 
(n = 447; 50%)
p value
  Left ventricular 23 (5) 4 (4) 0.592 6 (5) 3 (3) 0.741
  Right ventricular 162 (34) 43 (39) 0.313 53 (41) 38 (41) 0.795
  LVOT 7 (2) 3 (3) 0.358 3 (2) 2 (2) 1.000
  RVOT 84 (18) 15 (14) 0.315 21 (16) 14 (16) 1.000
 Ablation of ventricular tachycardia, n (%) 117 (7) 13 (2) 0.001 31 (7) 9 (2) 0.001
Patients at discharge, n (%) 1296 (72) 402 (66) 0.002 357 (80) 322 (72) 0.001
Presence of ICD overall, n (%) 643 (50) 217 (54) 0.126 214 (60) 190 (59) 0.816
 ICD 572 (89) 189 (87) 0.458 192 (91) 165 (87) 0.237
 s‑ICD 24 (4) 7 (3) 0.729 0 (0) 7 (4) 1.000
 CRT‑D 47 (7) 21 (10) 0.264 20 (9) 18 (10) 0.989
  Bipolar electrodes 17 (36) 6 (29) 0.541 8 (40) 5 (28) 0.428
  Multipolar electrodes 30 (64) 15 (71) 12 (60) 13 (72)
 Primary prevention 266 (41) 109 (50) 0.023 97 (45) 98 (52) 0.209
 Secondary prevention 377 (59) 108 (50) 117 (55) 92 (48)
Medication at discharge, n (%)
 Beta‑blocker 1010 (78) 336 (84) 0.014 311 (87) 279 (87) 0.857
 ACEi/ARB 904 (70) 323 (80) 0.001 249 (82) 266 (83) 0.930
 Statin 734 (57) 283 (71) 0.001 256 (72) 234 (73) 0.780
 Digitalis 133 (10) 69 (17) 0.001 50 (14) 59 (18) 0.126
 Amiodarone 169 (13) 88 (22) 0.001 66 (19) 69 (21) 0.338
 Sotalol 10 (0.8) 5 (1) 0.376 2 (0.6) 4 (1) 0.430
 Vitamin K antagonist 225 (17) 88 (22) 0.038 88 (25) 74 (23) 0.611
 NOAC 29 (2) 9 (2) 0.992 7 (2) 6 (2) 0.926
 Low molecular heparin 95 (7) 40 (10) 0.089 32 (9) 31 (10) 0.766
ACE angiotensin converting enzyme, ARB angiotensin II receptor blocker, CABG coronary artery bypass grafting, CRT-D cardiac resynchronization therapy with 
defibrillator, DM type 2 diabetes mellitus, ICD implantable cardioverter defibrillator, LVEF left ventricular ejection fraction, LVOT/RVOT left/right ventricular outflow 
tract, s-ICD subcutaneous ICD, NOAC novel oral anticoagulant, (N)STEMI (non) ST segment elevation myocardial infarction
Table 2 Antidiabetic medication in  diabetics 
with ventricular tachyarrythmias
DPP4 dipeptidyl peptidase-4, SGLT(2) sodium/glucose cotransporter 2
Before matching 
(n = 613; 25%)
After matching 
(n = 447; 50%)
Insulin, long‑acting 134 (33) 109 (34)
Insulin, short‑acting 61 (15) 50 (16)
Sulfonylurea 68 (17) 59 (18)
Metformin 61 (15) 50 (16)
Glitazone 2 (0.5) 2 (0.6)
DPP4 inhibitor 14 (4) 12 (4)
SGLT(2)‑inhibitor 1 (0.2) 1 (0.3)
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Discussion
The present study evaluates the prognostic impact of 
type 2 diabetes in consecutive high-risk patients present-
ing with ventricular tachyarrhythmias on admission.
This real-world data suggests that high-risk patients 
presenting with ventricular tachyarrhythmias on admis-
sion reveal higher long-term all-cause mortality in the 
presence of diabetes. Respectively, increasing rates 
of secondary endpoints, including in-hospital death 
at index, all-cause mortality at 30  days and long-term 
mortality in patients surviving index hospitalization 
were observed in diabetics compared to non-diabetics. 
Prognostic differences of long-term all-cause mortality 
for diabetics were verified in several subgroups even 
after multivariable adjustment including males, 
age > 70 years, VT, AMI, NSTEMI, overall CAD, multi-
vessel CAD and ICD-recipients, respectively with indi-
cation for primary prevention. This study identifies the 
presence of type 2 diabetes as a robust predictor of all-
cause mortality in patients presenting with ventricular 
tachyarrhythmias straight from the admission scenario, 
whereas early cardiac death at 24 h and rehospitaliza-
tion due to recurrent ventricular tachyarrhythmias 
were not affected by the presence of type 2 diabetes.
The presence of diabetes is an established cardiovas-
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Fig. 1 Kaplan Meier survival curves demonstrating higher long‑term all‑cause mortality before (left panel) and after propensity score matching 
(right panel) in diabetics presenting with ventricular tachyarrhythmias
Table 3 Unmatched  uni- and  multivariable hazard ratios to  predict the  primary prognostic endpoint of  long-term all-
cause mortality at 2 years (n = 2422)
CI confidence interval, CKD chronic kidney disease, HR hazard ratio, ICD implantable cardioverter defibrillator, LVEF left ventricular ejection fraction
Level of significance p < 0.05; statistical trend p < 0.1
n (%) Univariable Multivariable
HR 95% CI p value HR 95% CI p value
Age > 70 years 1057 (44) 1.924 1.714–2.210 0.001 1.560 1.305–1.866 0.001
Male gender 1728 (72) 0.945 0.822–1.086 0.428 1.299 1.069–1.579 0.008
Chronic kidney disease 1188 (49) 3.637 3.136–4.218 0.001 2.792 2.293–3.400 0.001
Acute myocardial infarction 687 (28) 1.422 1.245–1.624 0.001 0.719 0.587–0.881 0.001
LVEF < 55% 1247 (52) 1.622 1.332–1.976 0.001 1.861 1.509–2.294 0.001
Coronary artery disease 1490 (62) 0.959 0.842–1.091 0.521 0.938 0.766–1.147 0.531
Cardiopulmonary resuscitation 1256 (52) 2.312 2.146–2.491 0.001 1.841 1.657–2.045 0.001
Presence of an ICD, overall 860 (36) 0.207 0.172–0.248 0.001 0.245 0.196–0.306 0.001
Diabetes 613 (25) 1.513 1.322–1.731 0.001 1.209 1.010–1.447 0.039
Page 8 of 12Weidner et al. Cardiovasc Diabetol  (2018) 17:125 
rates of myocardial infarction, stroke and both all-cause 
and cardiovascular mortality in the general population 
[17, 18]. Diabetics without prior myocardial infarction 
reveal a comparable risk as non-diabetics with prior 
myocardial infarction regarding future occurrence of 
myocardial infarction and present with  higher rates of 
cardiac rehospitalisation [17, 19]. The increased risk of 
mortality related to diabetes has been demonstrated in 
patients suffering from CAD, especially multi-vessel-
CAD, where coronary artery bypass grafting (CABG) was 
proven as the best type of coronary revascularization in 
terms of mortality reduction compared to PCI [20–23]. 
The vascular system of diabetics is affected by oxidative 
stress, endothelial dysfunction, atherogenesis and vas-
cular remodeling alleviating coronary atherosclerosis, 
but also diabetic neuropathy [24, 25]. Diabetic neuropa-
thy promotes silent myocardial ischemia, which in turn 
may mimic typical angina and further signs of myocardial 
infarction [26]. Changes in lifestyle and effective anti-
diabetic medical therapy may significantly reduce lev-
els of Hba1c below the recommended treatment target 
of 7% in diabetics, which may at the same time attenu-
ate CAD development and improve prognosis [18, 27, 
28]. In clear contrast, the prognostic impact of diabetes 
in CAD patients presenting with ventricular tachyar-
rhythmias has rarely been investigated. In this respect, 
the present study delivers novel evidence, demonstrating 
the adverse prognostic impact of diabetes on long-term 
Table 4 Unmachted  univariable and  multivariable hazard ratios for  the  association of  diabetics with  the  primary 
prognostic endpoint of long-term all-cause mortality at 2 years in pre-specified sub-groups
CI confidence interval, HR hazard ratio, LVEF left ventricular ejection faction
Level of significance p < 0.05; statistical trend p < 0.1
a Multivariable models were adjusted for age, gender, chronic kidney disease, ventricular tachyarrhythmias, LV dysfunction, CPR, AMI and presence of an activated 
ICD (overall)
n (%) Univariable Multivariablea
HR 95% CI p value HR 95% CI p value
Total cohort 2422 (100) 1.513 1.322–1.731 0.001 1.209 1.010–1.447 0.039
Females 684 (28) 1.472 1.144–1.895 0.003 0.881 0.606–1.280 0.506
Males 1738 (72) 1.528 1.303–1.792 0.001 1.328 1.080–1.632 0.007
Age < 70 years 1365 (56) 1.564 1.258–1.945 0.001 1.189 0.950–1.488 0.131
Age > 70 years 1057 (44) 1.245 1.047–1.481 0.013 1.369 1.019–1.840 0.037
Ventricular tachycardia 1364 (56) 2.030 1.658–2.486 0.001 1.351 1.041–1.754 0.024
Ventricular fibrillation 1058 (44) 1.222 1.018–1.466 0.032 1.039 0.803–1.344 0.771
Chronic kidney disease 1194 (49) 1.267 1.084–1.481 0.003 1.206 0.984–1.478 0.071
No chronic kidney disease 1228 (51) 1.564 1.170–2.089 0.002 1.206 0.819–1.776 0.342
Acute myocardial infarction 691 (29) 1.291 1.020–1.634 0.033 1.569 1.144–2.150 0.005
ST segment elevation myocardial infarction 237 (10) 1.155 0.723–1.846 0.546 1.441 0.711–2.922 0.311
Non segment elevation myocardial infarction 454 (19) 1.309 0.995–1.721 0.054 1.692 1.180–2.425 0.004
Coronary artery disease, overall 1490 (62) 2.113 1.687–2.646 0.001 1.327 1.078–1.634 0.008
Coronary multivessel disease 721 (30) 1.221 0.953–1.563 0.114 1.516 1.110–2.070 0.009
No coronary artery disease 932 (39) 1.306 1.103–1.547 0.002 0.943 0.653–1.362 0.753
LVEF ≥ 55% 532 (22) 2.494 1.725–3.606 0.001 1.248 0.835–1.866 0.280
LVEF < 55% 1247 (51) 1.600 1.320–1.941 0.001 1.192 0.975–1.457 0.086
Implantable cardioverter defibrillator 860 (36) 2.046 1.447–2.893 0.001 1.859 1.272–2.715 0.001
 Primary prevention 397 (16) 2.736 1.688–4.436 0.001 1.902 1.116–3.242 0.018
 Secondary prevention 463 (20) 1.577 0.957–2.600 0.074 1.651 0.940–2.900 0.081
No implantable cardioverter defibrillator 1562 (64) 1.466 1.266–1.698 0.001 1.086 0.885–1.332 0.430
Table 5 Unmatched  univariable hazard ratios 
for  the  association of  anti-diabetic therapies 
with  the  primary prognostic endpoint of  all-cause 
mortality at 2 years
CI confidence interval, HR hazard ratio
Level of significance p < 0.05; statistical trend p < 0.1
n (%) Univariable
HR 95% CI p value
Insulin dependent 148 (37) 1.603 1.087–2.362 0.017
Metformin 61 (15) 0.256 0.104–0.628 0.003
Oral antidiabetic drugs 84 (21) 0.493 0.270–0.900 0.021
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all-cause mortality at 2  years even in the subgroups of 
AMI, NSTEMI, overall CAD and multi-vessel CAD.
Diabetic cardiomyopathy is another consecutive 
comorbidity, which is defined as concomitant heart fail-
ure in the absence of arterial hypertension and CAD 
[29]. The metabolic milieu in diabetics is characterized 
by hyperglycemia, increased fatty acids, triacylglyc-
erols, inflammatory cytokines and hyperinsulinemia. 
These alterations sustain structural changes of the myo-
cardium due to loss of cardiolipins with consecutive 
intra-myocardial lipid-accumulation [30, 31]. Modern 
concepts of optimal therapy monitoring as well as of pre-
diction of heart failure deterioration and rehospitaliza-
tion, especially in diabetic ICD recipients comprise the 
introduction of tele-monitoring systems. Their prognos-
tic benefits in terms of reduction of all-cause and car-
diovascular mortality is debated [32]. The present study 
has not implied any kind of tele-monitoring, which may 
in future improve further  the management of diabetic 
heart failure patients even in the presence of ventricular 
tachyarrhythmias.
The metabolic syndrome is associated with  co-exist-
ing  obesity, hyperlipidemia, arterial hypertension and 
(pre-) diabetes [33, 34]. Obese patients are associated 
with a two to three-fold higher risk for CAD than non-
obese patients alongside an  increased risk of mortality 
[35, 36]. Whether obese patients are also associated with 
an increased risk for ventricular tachyarrhythmias com-
pared to non-obese patients is controversial [34, 37]. 
Both obese and non-obese patients with mild stages of 
systolic heart failure reveal a comparable risk of ventricu-
lar tachyarrhythmias and comparable benefit from CRT 
therapy [34]. The metabolic syndrome itself may impact 
cardiac electrophysiological alterations and response to 
CRT-D therapy [33], which may be reflected by altera-
tions of thresholds of CRT-D leads parameters [33] lead-
ing to impaired response even at long-term follow-up 
[33, 38, 39]. Accordingly, electrocardiographic changes 
are found in diabetics potentially related to transmural 
dispersion of repolarization in terms of QRS and QT 
prolongation compared to non-diabetics [24]. Besides 
simple ECG recordings [40], novel biomarkers reflecting 
diabetes, heart failure and the metabolic syndrome, such 
as natriuretic peptides and neutrophil gelatinase-associ-
ated lipocalin (NGAL) [41–46] may reveal the potential 
to improve risk-stratification in terms of prediction of all-
cause and cardiovascular mortality in high-risk patients 
with ventricular tachyarrhythmias in future [45, 46].
Age has been identified as a significant risk factor for 
cardiovascular-related morbidity and mortality [47]. 
In  the present study diabetics > 70  years were associ-
ated with a 1.3-fold higher risk of death at 2 years, where 
Table 6 Primary and secondary endpoints
ICU invasive care unit, IQR interquartile range
Before matching (n = 2411) After matching (n = 894)
Non‑diabetics 
(n = 1798; 75%)
Diabetics (n = 613; 
25%)
p value Non‑diabetics 
(n = 447; 50%)
Diabetics (n = 447; 
50%)
p value
Primary endpoint, n (%)
 All cause‑mortality, at 
2 years
651 (36) 314 (51) 0.001 146 (33) 204 (46) 0.001
Secondary endpoints, n (%)
 Cardiac death, at 24 h 308 (17) 119 (19) 0.201 47 (11) 63 (14) 0.103
 All cause‑mortality, at 
30 days
488 (27) 202 (33) 0.006 87 (19) 120 (27) 0.009
 In‑hospital death, at 
index
502 (28) 211 (34) 0.002 91 (20) 126 (28) 0.006
 All‑cause mortality, 
after discharge
149 (8) 103 (17) 0.001 55 (12) 78 (17) 0.050
 Rehospitalization for 
ventricular tachyar‑
rhythmias
120 (9) 35 (9) 0.737 32 (9) 25 (8) 0.574
Follow up times
 Hospitalization total; 
days [median (IQR)]
10 (4–18) 13 (6–23) 0.008 12 (7–23) 14 (7–24) 0.277
 ICU time; days [median 
(IQR)]
2 (0–7) 4 (1–9) 0.001 3 (0–8) 4 (1–9) 0.005
 Follow‑up; days [mean; 
median (range)]
1488; 1087; (0–5106) 1005; 299 (0–5106) 0.001 1650; 1434 (0–5004) 1158; 541 (0–5106) 0.008
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concomitant heart failure is usually present. It may be 
speculated whether the prognostic benefit of an ICD 
therapy may become overt  in the elderly diabetic, since 
they may die from increasing co-morbidities without 
effective utilization of their device [48, 49]. Whether this 
may concern diabetics with documented episodes of ven-
tricular tachyarrhythmias awaits further research.
Novel oral antidiabetics were shown to decrease car-
diovascular mortality [21, 22]. The biguanide metformin 
and the sodium/glucose cotransporter 2 (SGLT2) inhibi-
tor empagliflozin were associated with a significant 
reduction of all-cause mortality and cardiovascular 
events in diabetics [36, 50]. The prognostic impact of 
incretin and its analogs on mortality or cardiovascular 
events is currently debated, since no reduction of major 
adverse cardiac events was demonstrated in patients with 
and without CAD by the dipeptidyl peptidase-4 (DPP-
4) inhibitor sitagliptin [51], whereas observational stud-
ies demonstrated adverse prognosis in STEMI/NSTEMI 
patients without incretin therapy [21, 22]. Evaluation 
of pharmacological effects of novel antidiabetic drugs 
was beyond the scope of the present study, where only 
a minor number of patients were treated by these ther-
apeutics. The univariable prognostic benefits in terms 
of mortality reduction seen for metformin and overall 
oral antidiabetics do not allow reliable conclusions for 
patients with ventricular tachyarrhythmias on admission.
In summary, this study demonstrates increasing all-
cause mortality at 2-years in diabetics compared to non-
diabetics presenting with ventricular tachyarrhythmias 
on admission. Respectively, increasing rates of secondary 
endpoints, including in-hospital death at index, all-cause 
mortality at 30 days and long-term mortality in patients 
surviving index hospitalization were seen in diabetics 
compared to non-diabetics. Therefore, the presence of 
diabetes represents a robust predictor of all-cause mor-
tality in patients presenting with ventricular tachyar-
rhythmias, as proven also in several sub-groups. The 
present results add to the knowledge of previous diabetes 
studies highlighting the need for a better risk stratifica-
tion of high risk diabetics presenting with ventricular 
tachyarrhythmias focussing on improvement of effective 
diagnostics and therapies.
Study limitations
This observational and retrospective registry-based anal-
ysis reflects a realistic picture of consecutive health-care 
supply of high-risk patients presenting with ventricu-
lar tachyarrhythmias. Lost to follow-up rate regarding 
the evaluated endpoint of all-cause mortality was mini-
mal. Although heterogeneity within the study popula-
tion was controlled by a stepwise statistical approach 
including multivariable adjustment and propensity score, 
some minor differences were still seen e.g. for chronic 
kidney disease. This may reflect the presence of diabetic 
nephropathy in this cohort. Patients not surviving out of 
hospital cardiac arrest were not transferred to the heart 
centre and therefore were not included in this study. All 
clinical data was documented reliably by individual car-
diologists, who were blinded to the final analysis. They 
documented their results  during routine clinical care, 
which alleviates the use of an independent clinical event 
committee. The present study did not assess data on body 
mass index (BMI), digitalis, amiodarone, sotalol, con-
tinuous monitoring systems or novel cardiac biomark-
ers. Future randomized or even multicenter studies may 
reevaluate the results of the present study.
Conclusions
This real-world data suggests that high-risk patients pre-
senting with ventricular tachyarrhythmias on admission 
are associated with increasing all-cause mortality in the 
presence of diabetes.
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